Sc Bio

About Sc Bio

SC-BIO Inc., established in October 2021, is a South Korean biotechnology firm specializing in the development of next-generation immuno-oncology and targeted cancer therapies. The company was founded by CEO Chang Hoon Lee, Ph.D., an immunologist with over two decades of experience in biomedical research and development. Dr. Lee previously served as a principal investigator at the Korea Research Institute of Chemical Technology and a senior researcher at the NIH in the USA, contributing to numerous technical transfers, patents, and scientific publications in the field of immunotherapy. His expertise in immuno-oncology forms the foundation of SC-BIO's strategic direction.

Operating from its headquarters and research facilities in Daejeon, the company pursues a business model centered on the discovery and preclinical development of novel small-molecule drug candidates. Its primary focus is to advance these candidates through to the Investigational New Drug (IND) application stage, with a goal of out-licensing the assets to larger pharmaceutical partners for clinical development and commercialization. SC-BIO has secured significant venture capital, with a cumulative total of 17 billion won from Series A and pre-A funding rounds, backed by investors such as Magna Investment, L&S Venture Capital, and Korea Investment Partners (KIP). This capital is being deployed to advance its lead pipeline assets.

The company's product pipeline features small-molecule compounds designed to modulate the tumor microenvironment and enhance anti-cancer immune responses. Its lead candidate, SCB001, targets CD73, an enzyme that suppresses immune cell activity within tumors. In preclinical animal models, SCB001 has demonstrated superior efficacy and safety compared to competing drugs in development. Another key asset, SCB002, is a Sirt6-targeted therapeutic. Both programs are progressing through preclinical development, with IND submissions targeted for 2024. SC-BIO's internal capabilities include facilities for compound synthesis and animal testing, which investors have noted as a key strength, enabling rapid development progress.